Clinical characteristics of 96 patients with IVLBCL
| Phenotype . | Total . | CD5+ or CD5−CD10+* . | CD5−CD10− . | CD5+CD10− . | P† . | P‡ . |
|---|---|---|---|---|---|---|
| No. of patients | 96 | 12 | 53 | 31 | — | — |
| GCB | 12/71 (17) | 12/12 (100) | 0/35 (0) | 0/24 (0) | — | — |
| Age at diagnosis, y | ||||||
| Median | 67 | 68.5 | 67 | 68 | .455 | .667 |
| Range | 41-85 | 42-81 | 41-85 | 44-84 | — | — |
| Older than 60 | 66 (69) | 10 (83) | 35 (66) | 21 (68) | .873 | .489 |
| Sex, male | 50 (52) | 5 (42) | 27 (51) | 18 (58) | .528 | .714 |
| Performance status, above 1 | 79 (82) | 11 (92) | 42 (79) | 26 (84) | .602 | .444 |
| Serum LDH level: high§ | 89 (93) | 12 (100) | 48 (91) | 29 (94) | .633 | .581 |
| Stage: III or IV | 87 (91) | 11 (92) | 47 (89) | 29 (94) | .463 | > .999 |
| Extranodal involvement | 96 (100) | 12 (100) | 53 (100) | 31 (100) | — | — |
| Extranodal involvement, more than 1 site | 65 (68) | 7 (58) | 38 (72) | 20 (65) | .492 | .299 |
| IPI | ||||||
| Low | 2 (2) | 0 (0) | 2 (4) | 0 (0) | — | — |
| Low-intermediate | 6 (6) | 0 (0) | 3 (6) | 3 (10) | — | — |
| High-intermediate | 16 (17) | 2 (17) | 11 (21) | 3 (10) | > .999¶ | .581¶ |
| High | 72 (75) | 10 (83) | 37 (70) | 25 (81) | .276 | .722 |
| B symptoms present | 73 (76) | 10 (83) | 37 (70) | 26 (84) | .151 | .488 |
| Hepatomegaly | 53 (55) | 5 (42) | 31 (58) | 17 (55) | .744 | .366 |
| Splenomegaly | 64 (67) | 9 (75) | 31 (58) | 24 (77) | .078# | .520 |
| Respiratory signs and symptoms | 33 (34) | 2 (17) | 18 (34) | 13 (42) | .465 | .202 |
| Neurologic signs and symptoms | 26 (27) | 3 (25) | 19 (36) | 4 (13) | .023# | .742 |
| Skin lesions | 14 (15) | 3 (25) | 8 (15) | 3 (10) | .739 | .382 |
| Hemophagocytosis in BM | 54/89 (61) | 6/12 (50) | 20/47 (64) | 18/30 (60) | .735 | .717 |
| Tumor cells in BM | 67/89 (75) | 9/12 (75) | 31/47 (66) | 27/30 (90) | .017# | > .999 |
| Tumor cells in PB | 23 (24) | 5 (42) | 4 (8) | 14 (45) | < .001# | .113 |
| Anemia‖ | 63 (66) | 9 (75) | 38 (72) | 16 (52) | .064 | .739 |
| Thrombocytopenia, less than 100 × 109/L | 56 (58) | 10 (83) | 24 (45) | 22 (71) | .022 | .049 |
| Leukocytopenia, less than 4 × 109/L | 26 (27) | 5 (42) | 15 (28) | 6 (19) | .361 | .143 |
| Albumin level, less than 30 g/L | 40/86 (47) | 6/10 (60) | 23/49 (47) | 11/27 (41) | .603 | .735 |
| Bilirubin level, 15 mg/L or higher | 17/86 (20) | 1/11 (9) | 9/47 (19) | 7/28 (25) | .550 | .672 |
| Creatinine level, 15 mg/L or higher | 9/91 (10) | 0/11 (0) | 5/51 (10) | 4/29 (14) | .716 | .337 |
| CRP level, 50 mg/L or higher | 54/90 (60) | 3/12 (25) | 30/48 (63) | 21/30 (70) | .498 | .010 |
| sIL-2R level 5 × 103 U/mL or higher | 37/66 (56) | 6/10 (60) | 19/34 (56) | 12/22 (55) | .922 | .731 |
| Anthracycline-based chemotherapy | 62/94 (66) | 10/12 (83) | 31/51 (61) | 21/31 (68) | .642 | .116 |
| Phenotype . | Total . | CD5+ or CD5−CD10+* . | CD5−CD10− . | CD5+CD10− . | P† . | P‡ . |
|---|---|---|---|---|---|---|
| No. of patients | 96 | 12 | 53 | 31 | — | — |
| GCB | 12/71 (17) | 12/12 (100) | 0/35 (0) | 0/24 (0) | — | — |
| Age at diagnosis, y | ||||||
| Median | 67 | 68.5 | 67 | 68 | .455 | .667 |
| Range | 41-85 | 42-81 | 41-85 | 44-84 | — | — |
| Older than 60 | 66 (69) | 10 (83) | 35 (66) | 21 (68) | .873 | .489 |
| Sex, male | 50 (52) | 5 (42) | 27 (51) | 18 (58) | .528 | .714 |
| Performance status, above 1 | 79 (82) | 11 (92) | 42 (79) | 26 (84) | .602 | .444 |
| Serum LDH level: high§ | 89 (93) | 12 (100) | 48 (91) | 29 (94) | .633 | .581 |
| Stage: III or IV | 87 (91) | 11 (92) | 47 (89) | 29 (94) | .463 | > .999 |
| Extranodal involvement | 96 (100) | 12 (100) | 53 (100) | 31 (100) | — | — |
| Extranodal involvement, more than 1 site | 65 (68) | 7 (58) | 38 (72) | 20 (65) | .492 | .299 |
| IPI | ||||||
| Low | 2 (2) | 0 (0) | 2 (4) | 0 (0) | — | — |
| Low-intermediate | 6 (6) | 0 (0) | 3 (6) | 3 (10) | — | — |
| High-intermediate | 16 (17) | 2 (17) | 11 (21) | 3 (10) | > .999¶ | .581¶ |
| High | 72 (75) | 10 (83) | 37 (70) | 25 (81) | .276 | .722 |
| B symptoms present | 73 (76) | 10 (83) | 37 (70) | 26 (84) | .151 | .488 |
| Hepatomegaly | 53 (55) | 5 (42) | 31 (58) | 17 (55) | .744 | .366 |
| Splenomegaly | 64 (67) | 9 (75) | 31 (58) | 24 (77) | .078# | .520 |
| Respiratory signs and symptoms | 33 (34) | 2 (17) | 18 (34) | 13 (42) | .465 | .202 |
| Neurologic signs and symptoms | 26 (27) | 3 (25) | 19 (36) | 4 (13) | .023# | .742 |
| Skin lesions | 14 (15) | 3 (25) | 8 (15) | 3 (10) | .739 | .382 |
| Hemophagocytosis in BM | 54/89 (61) | 6/12 (50) | 20/47 (64) | 18/30 (60) | .735 | .717 |
| Tumor cells in BM | 67/89 (75) | 9/12 (75) | 31/47 (66) | 27/30 (90) | .017# | > .999 |
| Tumor cells in PB | 23 (24) | 5 (42) | 4 (8) | 14 (45) | < .001# | .113 |
| Anemia‖ | 63 (66) | 9 (75) | 38 (72) | 16 (52) | .064 | .739 |
| Thrombocytopenia, less than 100 × 109/L | 56 (58) | 10 (83) | 24 (45) | 22 (71) | .022 | .049 |
| Leukocytopenia, less than 4 × 109/L | 26 (27) | 5 (42) | 15 (28) | 6 (19) | .361 | .143 |
| Albumin level, less than 30 g/L | 40/86 (47) | 6/10 (60) | 23/49 (47) | 11/27 (41) | .603 | .735 |
| Bilirubin level, 15 mg/L or higher | 17/86 (20) | 1/11 (9) | 9/47 (19) | 7/28 (25) | .550 | .672 |
| Creatinine level, 15 mg/L or higher | 9/91 (10) | 0/11 (0) | 5/51 (10) | 4/29 (14) | .716 | .337 |
| CRP level, 50 mg/L or higher | 54/90 (60) | 3/12 (25) | 30/48 (63) | 21/30 (70) | .498 | .010 |
| sIL-2R level 5 × 103 U/mL or higher | 37/66 (56) | 6/10 (60) | 19/34 (56) | 12/22 (55) | .922 | .731 |
| Anthracycline-based chemotherapy | 62/94 (66) | 10/12 (83) | 31/51 (61) | 21/31 (68) | .642 | .116 |
Values before and after slash indicate numbers of positive and evaluable patients, respectively. In the absence of a slash, all patients are evaluable. Values in parentheses are percentages. P values less than .05 are italicized.
sIL-2R indicates soluble IL-2 receptor; and —, not applicable.
Including CD5−CD10+ (n = 7) and CD5+CD10+ types (n = 5).
CD5−CD10− IVLBCL (n = 53) versus CD5+CD10− IVLBCL (n = 31).
GCB type (n = 12: CD5−CD10+ [n = 7] and CD5+CD10+ [n = 5]) versus non-GCB type (n = 59: CD5−CD10− [n = 35] and CD5+CD10− [n = 24]) according to the decision tree proposed by Hans et al.15
Higher than upper limit of the standard range defined by each institution.
Defined as < 110 g/L hemoglobin or 3.50 × 1012/L red blood cell count.
High or high-intermediate versus low or low-intermediate.
Significant (P < .05) when CD5+ or CD5− CD10−IVLBCL was limited to the 59 cases of non-GCB type.